Direct-acting antiviral course (glecaprevir/pibrentasvir or sofosbuvir/velpatasvir)
8 weeks of glecaprevir/pibrentasvir or 12 weeks of sofosbuvir/velpatasvir
tests per year, US, one course of 8 or 12 weeks
“Based on these data, 8 weeks of glecaprevir/pibrentasvir or 12 weeks of sofosbuvir/velpatasvir is recommended for adults eligible for the simplified treatment algorithm.”
AASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm), 2020-02
- Kind of source
- Clinical guideline
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- A one-off curative course for treatment-naive adults without cirrhosis, so the prescription history is short.
Used in
Kept as evidence; no figure on the platform is computed from it yet.